Compare Elanco Animal Health Incorporated Common Stock (ELAN) vs Hafnia Limited Common Shares (HAFN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elanco Animal Health Incorporated Common Stock vs Hafnia Limited Common Shares — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.55 (market cap $11.20B), while Hafnia Limited Common Shares trades at $10.59 (market cap $5.76B). The key difference: Elanco Animal Health Incorporated Common Stock is the larger of the two by market cap, and Hafnia Limited Common Shares pays a 10.24% dividend while Elanco Animal Health Incorporated Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and Hafnia Limited Common Shares for 0 Days on average.
| ELAN | HAFN | |
|---|---|---|
Market Cap | $11.20B | $5.76B |
Volume | 3,345,224 | 1,835,725 |
Sector | Health | Industrials |
52-Week High | $26.84 | $10.92 |
52-Week Low | $19.80 | $5.21 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.58B | $6.37B |
Dividend Yield | — | 10.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elanco Animal Health Incorporated Common Stock
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →
